70 related articles for article (PubMed ID: 20018510)
1. Diaryl piperidines as CB1 receptor antagonists.
Scott JD; Li SW; Wang H; Xia Y; Jayne CL; Miller MW; Duffy RA; Boykow GC; Kowalski TJ; Spar BD; Stamford AW; Chackalamannil S; Lachowicz JE; Greenlee WJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):1278-83. PubMed ID: 20018510
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
[TBL] [Abstract][Full Text] [Related]
3. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
[TBL] [Abstract][Full Text] [Related]
4. Novel thioamide derivatives as neutral CB1 receptor antagonists.
Boström J; Olsson RI; Tholander J; Greasley PJ; Ryberg E; Nordberg H; Hjorth S; Cheng L
Bioorg Med Chem Lett; 2010 Jan; 20(2):479-82. PubMed ID: 20005704
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.
Griffith DA; Hadcock JR; Black SC; Iredale PA; Carpino PA; DaSilva-Jardine P; Day R; DiBrino J; Dow RL; Landis MS; O'Connor RE; Scott DO
J Med Chem; 2009 Jan; 52(2):234-7. PubMed ID: 19102698
[TBL] [Abstract][Full Text] [Related]
7. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
[TBL] [Abstract][Full Text] [Related]
8. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.
Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J
Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711
[TBL] [Abstract][Full Text] [Related]
10. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.
Kim JY; Seo HJ; Lee SH; Jung ME; Ahn K; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Jan; 19(1):142-5. PubMed ID: 19022666
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists.
Debenham JS; Madsen-Duggan CB; Walsh TF; Wang J; Tong X; Doss GA; Lao J; Fong TM; Schaeffer MT; Xiao JC; Huang CR; Shen CP; Feng Y; Marsh DJ; Stribling DS; Shearman LP; Strack AM; MacIntyre DE; Van der Ploeg LH; Goulet MT
Bioorg Med Chem Lett; 2006 Feb; 16(3):681-5. PubMed ID: 16263284
[TBL] [Abstract][Full Text] [Related]
12. Identification and hit-to-lead optimization of a novel class of CB1 antagonists.
Letourneau JJ; Jokiel P; Olson J; Riviello CM; Ho KK; McAleer L; Yang J; Swanson RN; Baker J; Cowley P; Edwards D; Ward N; Ohlmeyer MH; Webb ML
Bioorg Med Chem Lett; 2010 Sep; 20(18):5449-53. PubMed ID: 20719511
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
[TBL] [Abstract][Full Text] [Related]
14. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.
Boström J; Berggren K; Elebring T; Greasley PJ; Wilstermann M
Bioorg Med Chem; 2007 Jun; 15(12):4077-84. PubMed ID: 17433696
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the research and development of CB1 antagonists.
Smith RA; Fathi Z
IDrugs; 2005 Jan; 8(1):53-66. PubMed ID: 15650943
[TBL] [Abstract][Full Text] [Related]
16. The discovery of novel indole-2-carboxamides as cannabinoid CB(1) receptor antagonists.
Cowley PM; Baker J; Barn DR; Buchanan KI; Carlyle I; Clark JK; Clarkson TR; Deehan M; Edwards D; Goodwin RR; Jaap D; Kiyoi Y; Mort C; Palin R; Prosser A; Walker G; Ward N; Wishart G; Young T
Bioorg Med Chem Lett; 2011 Jan; 21(1):497-501. PubMed ID: 21075628
[TBL] [Abstract][Full Text] [Related]
17. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
[TBL] [Abstract][Full Text] [Related]
18. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists.
Lange JH; den Hartog AP; van der Neut MA; van Vliet BJ; Kruse CG
Bioorg Med Chem Lett; 2009 Oct; 19(19):5675-8. PubMed ID: 19699640
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
Lange JH; van der Neut MA; den Hartog AP; Wals HC; Hoogendoorn J; van Stuivenberg HH; van Vliet BJ; Kruse CG
Bioorg Med Chem Lett; 2010 Mar; 20(5):1752-7. PubMed ID: 20137935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
